Jawa Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 10-12-2024
- Paid Up Capital ₹ 4.88 M
as on 10-12-2024
- Company Age 31 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 Cr
as on 10-12-2024
- Satisfied Charges ₹ 2.48 Cr
as on 10-12-2024
- Revenue 123579.06%
(FY 2023)
- Profit 170855.92%
(FY 2023)
- Ebitda 147395.60%
(FY 2023)
- Net Worth 153063.70%
(FY 2023)
- Total Assets 147369.96%
(FY 2023)
About Jawa Pharmaceuticals (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.88 M.
The company currently has active open charges totaling ₹5.00 Cr. The company has closed loans amounting to ₹2.48 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajat Jawa, Ajay Soni, Santosh Jawa, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232RJ1993PTC007150
- Company No.
007150
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jan 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- LocationC, Rajasthan
- Telephone
- Email Address
- Website
-
- Social Media
Who are the key members and board of directors at Jawa Pharmaceuticals (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajat Jawa  | Managing Director | 31-Mar-1993 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aarav Jawa  | Director | 28-Feb-2020 | Current |
| Ajay Soni | Director | 10-Aug-2006 | Current |
| Santosh Jawa | Whole-Time Director | 13-Jan-1993 | Current |
Financial Performance of Jawa Pharmaceuticals (India).
Jawa Pharmaceuticals (India) Pvt. Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 123579.06% increase. The company also saw a substantial improvement in profitability, with a 170855.92% increase in profit. The company's net worth Soared by an impressive increase of 153063.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jawa Pharmaceuticals (India)?
In 2023, Jawa Pharmaceuticals (India) had a promoter holding of 100.00% and a public holding of 0.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Dec 2021 | ₹5.00 Cr | Open |
Kotak Mahindra Bank Limited Creation Date: 25 Jul 2014 | ₹2.00 Cr | Satisfied |
Indian Bank Creation Date: 05 Sep 2002 | - | Satisfied |
How Many Employees Work at Jawa Pharmaceuticals (India)?
Jawa Pharmaceuticals (India) has a workforce of 171 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jawa Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jawa Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
